

PART II. COMMENTS ON THE FINANCIAL REPORT

PART III. PATENT APPLICATIONS, PATENTS, COMMERCIAL AGREEMENTS, etc.

Use additional pages if needed. Include only those instances where portions of the relevant work/results were accomplished wholly or in part with WHO funds.

PART IV. TRAINING OPPORTUNITIES

Trainees (especially any from developing countries), including those supported by other sources, who have benefited directly or indirectly from this WHO funded project. Include position and home country.

PART V. BRIEF ABSTRACT

Include brief description of objectives, rationale, relevance, experimental design, and significant progress. Please note that one of the uses of this summary will be as part of generally distributed information packages describing the ongoing work to potential donors, etc., thus this abstract should be able to stand alone and be circulated to others. Do not exceed box.

Title of Project:

Investigator(s):

Institution(s):

SUMMARY:

PART VI. PUBLICATIONS, PRESENTATIONS, PUBLICATIONS SUBMITTED, etc.

*Use additional pages if needed. Only include publications where some or all of the work was carried out with WHO funds. Where appropriate, please remember to acknowledge WHO funds in your papers, etc. **Please also remember to supply us with 2 reprints of each publication.***

PART VII. DETAILED DESCRIPTION OF RESULTS

*Use additional pages if needed **maximum 6**. Please summarize then discuss all results obtained during the length of the project.*

The bottom part of this page will be returned to you upon receipt of **the original copy** of your report.

Please **add** the relevant information **in the two boxes** of this form.

GPV internal note: voucher sent back on.....

Name of Principal Investigator
and address:

Title of your research proposal:

Dear Sir/Madam,

This is to inform you that we safely received the above mentioned final report as follows:

- an advance copy by facsimile on
- the original on.....

This proposal will be submitted to the relevant IVR Steering Committee(s) for consideration during their annual meeting. You will be informed of the outcome of the discussion as soon as possible.

Thank you very much for your interest in IVR activities.

Yours sincerely,

Dr Marie-Paule Kieny
Director
Initiative for Vaccine Research